Faulty Dosing Device Prompts Recall of Infants' Tylenol

FRIDAY, Feb. 17 (HealthDay News) -- A potentially faulty dosing system on bottles of Infants' Tylenol has prompted McNeil Consumer Healthcare, a division of Johnson & Johnson, to recall all of the product.

The voluntary recall comes in response to some consumer complaints about the product's so-called SimpleMeasure dosing system, which dispenses measured doses of the medication.

The system includes a dosing syringe that an adult inserts into the cover at the top of the bottle. It's supposed to limit the amount of Tylenol that can be delivered in a single dose, according to the company.

In some cases, inserting the syringe pushed this "flow restrictor" into the bottle.

"Parents can continue to use the product as long as the flow restrictor is in place," Johnson & Johnson spokeswoman Bonnie Jacobs said. "If the flow restrictor does push into the bottle, then they should stop using it and contact us."

According to the company, there have been no adverse events reported due to the problem, "and the risk of a serious adverse medical event is remote."

Jacobs said she didn't know when Infants' Tylenol would be available again. "We're conducting a full review to determine why it's not performing as expected. We are looking at different options," she said.

The recall affects only Infants' Tylenol. Children's Tylenol, which is for use by children 2 years of age and older, remains on the market, Jacobs said.

More information

For more information, visit Johnson & Johnson.

SOURCE: Bonnie Jacobs, spokeswoman, Johnson & Johnson

Related Articles

Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.

Health News is provided as a service to Sharp Web site users by HealthDay. Sharp HealthCare nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please read the Terms of Use for more information.